About: Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment. Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response. In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response. (en)
Title	Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment. Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment. (en)
skos:prefLabel	Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment. Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment. (en)
skos:notation	RIV/61989592:15110/10:10215602!RIV11-MZ0-15110___
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(NS9627), P(NS9949)
http://linked.open...vai/riv/dodaniDat	2011
http://linked.open...aciTvurceVysledku	Skoumalová, Ivana Faber, Edgar INDRÁK, Karel Rohoň, Peter Rožmanová, Šárka Jarošová, Marie Divoká, Martina Adam, Tomáš Friedecký, David Mičová, Kateřina
http://linked.open.../riv/druhVysledku	D - Článek ve sborníku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	270063
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/10:10215602
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	UHPLC-TMS; correlation; treatment response; imatinib plasma levels (en)
http://linked.open.../riv/klicoveSlovo	correlation treatment response UHPLC-TMS imatinib plasma levels
http://linked.open...ontrolniKodProRIV	[BB5E5DD02710]
http://linked.open...v/mistoKonaniAkce	Barcelona, Spain
http://linked.open...i/riv/mistoVydani	Pavia
http://linked.open...i/riv/nazevZdroje	Haematologica: the hematology journal
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	10 (xsd:int)
http://linked.open...cetTvurcuVysledku	10 (xsd:int)
http://linked.open...vavai/riv/projekt	The role of cellular transport mechanisms in efficacy of imatinib mesylate treatment in patients with chronic myeloid leukemia The role of in vitro sensitivity to tyrosine kinase inhibitors estimation in management of patients with chronic myeloid leukemia
http://linked.open...UplatneniVysledku	2010
http://linked.open...iv/tvurceVysledku	Faber, Edgar Indrák, Karel Jarošová, Marie Divoká, Martina Rožmanová, Šárka ROHOŇ, Peter ADAM, Tomáš FRIEDECKÝ, David MIČOVÁ, Kateřina SKOUMALOVÁ, Ivana
http://linked.open...vavai/riv/typAkce	EUR - Evropská
http://linked.open...ain/vavai/riv/wos	000279051301143
http://linked.open.../riv/zahajeniAkce	2010-06-10 (xsd:date)
issn	0390-6078
number of pages	2 (xsd:int)
http://purl.org/ne...btex#hasPublisher	Fondazione Ferrata Storti
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 77 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software